Table 1.

Demographics of the samples analysed in the targeted assay (phase I)

	De novo PD	Healthy controls	Other neurological disorders (OND)	REM sleep behaviour disorder (iRBD)	p value (compared to healthy controls)
					De novo PD	iRBD	OND
Number of subjects	99	36	41	18
Sex (M/F)	49/50	20/15	29/12	10/8
M/F%	49/51	57/43	71/29	56/44
Age (mean ± SD)	67.1 ± 10.6	63.7 ± 6.5	70 ± 8.9	67.3 ± 8.3	8.3E-2	8.9E-2	8.4E-4
Range	41−87	52−77	49−82	51−77
UPDRS I (mean ± SD)	1.8 ± 1.8	0.5 ± 0.9	N/A	2.9 ± 2.5	6.1E-5	4.6E-6	N/A
Range	0−8	0−4	N/A	0−9
UPDRS II (mean ± SD)	8.7 ± 6.6	0.03 ± 0.2	N/A	3.1 ± 3.7	1.9E-12	1.4E-5	N/A
Range	0−29	0 − 1	N/A	0−11
UPDRS III (mean ± SD)	24.8 ± 13.9	0.3 ± 0.7	21.2 ± 13.3	2.6 ± 2.7	7.1E-19	1.6E-5	1.7E-13
Range	5−69	0−3	3−51	0−10
UPDRS total score (mean ± SD)	35.2 ± 18.3	0.7 ± 1.3	N/A	8.5 ± 7.2	1.4E-20	8.9E-8	N/A
Range	6−86	0−6	N/A	1−26
MMSE total score (mean ± SD)	28 ± 2.2	28.9 ± 1.4	26.6 ± 2.6	28.5 ± 1.8	2.8E-2	3.6E-1	2.5E-5
Range	25−30	26–30	19−30	25−30

OND consists of subjects with vascular parkinsonism (n = 10), essential tremor (n = 7), progressive supranuclear palsy; PSP (n = 7), multiple system atrophy; MSA (n = 3), corticobasal syndrome; CBS (n = 2), dementia with Lewy bodies; DLB (n = 2), drug-induced tremor (n = 2), dystonic tremor (n = 2), restless legs syndrome (n = 1), hemifacial spasm (n = 1), motoneuron disease (n = 1), amyotrophic shoulder neuralgia (n = 1), Alzheimer’s disease (n = 1). The significance between controls and the disease groups was tested by applying Student’s two-tailed t-test.

MMSE mini-mental state examination, UPDRS unified Parkinson’s disease rating scale.